CLEVELAND [April 23] /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced an Israeli biopharmaceutical company chose to standardize on the D ATATRAK ONE™ clinical research platform for its oncology program. Understanding the benefit of the unified platform, they will utilize multiple products and modules within the software suite – uEDC, including medical coding and uIRT, including both Randomization and Clinical Supplies Management – to reduce the cost of their clinical trials.
“Our new client has an exciting history of developing novel immunotherapy drug products,” stated Laurence P. Birch, D ATATRAK ’s Chairman of the Board and CEO. “Pairing our expansive technology with their innovative approach to drug development, we are able to reduce costs across their oncology drug program as well as accelerate their clinical trial timelines.”
D ATATRAK ONE™:
The D ATATRAK ONE™ Clinical Research Platform is an easy to use, cloud-based clinical enterprise solution that empowers Sponsors and CROs to efficiently design, deliver and manage clinical trials. From strategy and planning to resource management and study execution needs, clients manage their entire product portfolio in a single system with one username and password. D ATATRAK ’s unified clinical enterprise solution consists of seven products: uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR.
Join DATATRAK Thought Leaders:
- SlideShare
- The DATATRAK Blog
- Tweet: New Israeli Client Selects DATATRAK ONE™ for Oncology Program http://ow.ly/kjkmv
About D ATATRAK International, Inc.
D ATATRAK International is a worldwide technology and services company delivering unified eClinical™ solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK ’s Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net .
All contracts are subject to possible delays or cancellation or can change in scope in a positive or negative direction. Therefore, current backlog is not necessarily indicative of the Company’s future quarterly or annual revenue. Historically, backlog has been a poor predictor of the Company’s short-term revenue.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s report filed with the OTCQX Market on March 15, 2013 announcing its results for the fourth quarter and full year of 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
Contact:
Lisa Pahl, Director Marketing, D ATATRAK International, Inc., +1-979-393-9025
